Previous close | 1.4509 |
Open | 0.0000 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | 357 |
Market cap | N/A |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1420 |
Earnings date | 12 Apr 2024 - 16 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 i
In this article, we will be taking a look at the 15 highest quality probiotics for gut health. If you do not want to learn about the global probiotic market, head straight to the 5 Highest Quality Probiotics For Gut Health. Achieving optimal gut health is paramount for overall well-being, and selecting the highest quality […]
SARASOTA, Fla., March 05, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the final steps of GMP manufacturing and formulation of its drug candidate for its expected Phase IIA clinical trial. The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion. Oragenic